Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Li, Yajuan ^a   Yuan, Ying ^b   Tao, Kun ^a   Wang, Xin ^b   Xiao, Qing ^b   Huang, Zhenglan ^a   Zhong, Liang ^a   Cao, Weixi ^a   Wen, Jianping ^c   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB; MICRORNA; MICRORNA 203; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; UPREGULATION;

ADULT; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MICE; MICRORNAS; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84876177069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061858     Document Type: Article

References (20)

1. Druker BJ, (2003) Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 4: 963-971.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
3. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
4. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, et al. (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101: 1566-1569.
5. Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH, (2010) Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 95: 388-397.
6. Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, et al. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102: 2236-2239.
7. Ambros V, (2001) microRNAs: tiny regulators with great potential. Cell 107: 823-826.
8. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM, (2006) MicroRNA expression and function in cancer. Trends Mol Med 12: 580-587.
9. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, et al. (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506.
10. Peng Z, Luo HW, Yuan Y, Shi J, Huang SF, et al. (2011) Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes. Oncol Rep 25: 1381-1388.
11. Goldman JM, Melo JV, (2003) Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464.
12. Wilda M, Fuchs U, Wossmann W, Borkhardt A, (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21: 5716-5724.
13. Chekulaeva M, Filipowicz W, (2009) Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21: 452-460.
14. Lee YS, Dutta A, (2006) MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 7: 560-564.
15. Wang V, Wu W, (2009) MicroRNA-based therapeutics for cancer. BioDrugs 23: 15-23.
16. Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, et al. (2011) MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 10: 1121-1131.
17. Sonkoly E, Wei T, Pavez Lorie E, Suzuki H, Kato M, et al. (2010) Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol 130: 124-134.
18. Bueno MJ, Perez de Castro I, Malumbres M, (2008) Control of cell proliferation pathways by microRNAs. Cell Cycle 7: 3143-3148.
19. Bo J, Yang G, Huo K, Jiang H, Zhang L, et al. (2011) microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J 278: 786-792.
20. Oltvai ZN, Milliman CL, Korsmeyer SJ, (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.